MSMahnoor Shahab

Mahnoor Shahab

*This is an algorithmically generated author record based on publicly available information.

Mahnoor Shahab has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Efficacy and outcomes of 360° laser retinopexy versus focal laser photocoagulation for retinal detachment

    by Abu Bakar Butt, Shreyas Bhat, Mahnoor Shahab, Andrew Mihalache, Cindy Zhang, Melody Tong, Tina Felfeli, Efrem D. Mandelcorn

  • Open Access

    Major Adverse Cardiac Events with Ondansetron: A Systematic Review

    by Michael Cristian Garcia, Bhavya Gandhi, Faisal Quadri, Mahnoor Shahab, Kassie Rong, Genevieve Ramnarine, Ishleen Sudan, Sophia Zhang, Michelle Yu, Sara Mojdehi, et al.

    Ondansetron frequently triggers medication safety alerts because of its listing as a ‘known risk’ QT interval‐prolonging medication. We aimed to summarize literature on QT‐prolongation‐related major adverse cardiac events associated with ondansetron. We searched Medline, Embase, International Pharmaceutical Abstracts, and Cochrane Central for randomized controlled trials comparing ondansetron to placebo in adults. Major adverse cardiac events (MACE) included death, nonfatal cardiac arrest, ventricular tachyarrhythmia including torsades de pointes, seizure, or syncope. Random‐effects meta‐analyses were performed with a treatment arm continuity correction for single‐ and double‐zero event studies. We included 170 randomized trials ( n = 23,421, 70.7% female, 48.3% aged >65), 119 trials (70.0%) involving surgical patients, and 77 (45.4%) including electrocardiograms. Mean follow‐up was 10 days (SD: 21.8) (median: 1 day). Risk of bias was high for 11.8% of trials, and low for 28.8%. Only seven MACE (all deaths) were reported. Ondansetron was not associated with increased mortality ( n = 23,421, RR: 1.03, 95% CI: 0.76–1.39, I 2 = 0.0%), or arrhythmias. Lack of events precluded prespecified meta‐analyses. Further research on QT‐prolonging medications and their attributed adverse cardiac events and medication alert optimization is needed.